Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2023-12-21 eCollection Date: 2023-03-01 DOI:10.2217/mmt-2023-0005

Oleksandr Dudin, Ozar Mintser, Nazarii Kobyliak, Dmytro Kaminskyi, Roman Shabalkov, Alina Matvieieva, Olga Sukhanova, Antonina Kalmykova, Denys Kozakov, Artem Mashukov, Oksana Sulaieva

{"title":"Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population.","authors":"Oleksandr Dudin, Ozar Mintser, Nazarii Kobyliak, Dmytro Kaminskyi, Roman Shabalkov, Alina Matvieieva, Olga Sukhanova, Antonina Kalmykova, Denys Kozakov, Artem Mashukov, Oksana Sulaieva","doi":"10.2217/mmt-2023-0005","DOIUrl":null,"url":null,"abstract":"Aim: This study aimed to investigate the incidence of BRAF mutation in cutaneous melanoma in the Ukrainian population with respect to clinical and histopathological data.Materials & methods: This single-center retrospective cohort study enrolled 299 primary CM with known BRAF status assessed by RT-PCR.Results: The overall BRAF mutation rate was 56.5% in CM and demonstrated a link with the younger age (p < 0.001), anatomical site (p < 0.001) and histological type of CM (p = 0.022). BRAF-positive CM possessed a slightly higher mitotic rate (p = 0.015) and Breslow thickness (p = 0.028) but did not relate to tumor-infiltrating lymphocytes.Conclusion: The high rate of BRAF mutations in CM patients in the Ukrainian cohort was associated with superficial spreading histology, higher depth of invasion and proliferation.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784762/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2023-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study aimed to investigate the incidence of BRAF mutation in cutaneous melanoma in the Ukrainian population with respect to clinical and histopathological data.

Materials & methods: This single-center retrospective cohort study enrolled 299 primary CM with known BRAF status assessed by RT-PCR.

Results: The overall BRAF mutation rate was 56.5% in CM and demonstrated a link with the younger age (p < 0.001), anatomical site (p < 0.001) and histological type of CM (p = 0.022). BRAF-positive CM possessed a slightly higher mitotic rate (p = 0.015) and Breslow thickness (p = 0.028) but did not relate to tumor-infiltrating lymphocytes.

Conclusion: The high rate of BRAF mutations in CM patients in the Ukrainian cohort was associated with superficial spreading histology, higher depth of invasion and proliferation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

皮肤黑色素瘤中 BRAF 突变的发生率：对乌克兰人群的组织病理学和分子分析。

目的：本研究旨在根据临床和组织病理学数据，调查乌克兰人群中皮肤黑色素瘤BRAF突变的发生率：这项单中心回顾性队列研究共纳入 299 例通过 RT-PCR 评估 BRAF 状态的原发性皮肤黑色素瘤：BRAF 阳性 CM 的有丝分裂率（p = 0.015）和布瑞斯洛厚度（p = 0.028）略高，但与肿瘤浸润淋巴细胞无关：乌克兰队列中 CM 患者的 BRAF 突变率较高，这与表层扩散组织学、较高的侵袭深度和增殖有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.